We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editor's Correspondence |

Hypogonadism and Osteoporosis in Men

Nasser Mikhail, MD, MSc
Arch Intern Med. 2003;163(10):1237. doi:10.1001/archinte.163.10.1237-a.
Text Size: A A A
Published online


I followed with great interest the data reported by Kiebzak et al1 regarding the underdiagnosis and undertreatment of osteoporosis in men. Only 7% of their male patients had a diagnosis of osteoporosis prior to hip fracture, and fewer than 5% were taking treatment of any kind at hospital discharge. Moreover, in their medical chart review, the authors stated that osteoporosis risk factors were not consistently documented in patients' medical records. Specifically, there was no mention of hypogonadism, a well-established risk factor for osteoporosis in men. Clearly, the previous data unravel the profound unawareness of risk factors and treatment of osteoporosis in the male sex. In fact, hypogonadism is the commonest cause of secondary osteoporosis in men, occurring in up to 20% of men with symptomatic vertebral fractures and 50% of elderly men with hip fractures.2 In the series of Kiebzak et al,1 only 5 of the 110 male patients with hip fracture had a documented diagnosis of hypogonadism, a finding that underscores the lack of awareness of gonadal failure being an important risk factor for osteoporosis in men. In this regard, I disagree with the authors for not considering testosterone as a treatment for osteoporosis in males, and in their claim that there is little information in the literature to support its use as an osteoporosis treatment (page 2218 of the article). Indeed, testosterone supplementation in hypogonadal men with osteoporosis increases bone mineral density,3 decreases bone resorption, and stimulates bone formation.4 In addition, such therapy can ameliorate concomitant abnormalities that contribute to the pathogenesis of hypogonadal male osteoporosis, such as low circulating levels of estrogen, calcitonin, 1,25 dihydroxyvitamin D, and negative calcium balance.4 Furthermore, the improvement of muscle strength as result of testosterone administration may potentially decrease the risk of falls. Although long-term randomized studies specifically designed to assess the effect of testosterone replacement on the incidence of fractures are lacking, this should not be a reason to overlook routine screening for gonadal failure in men with osteoporosis. Until such studies become available, it is worthwhile to offer testosterone replacement therapy to patients with proven hypogonadism in addition to the standard treatment of osteoporosis. It should be emphasized that hip fracture in men is a true public health problem. Multiple studies,5 including that of Kiebzak et al,1 have repeatedly shown higher mortality following hip fracture in men than in women. Thus, it is vitally important to identify and correct any remediable cause of skeletal deterioration in the male population.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Vitamin D and chronic diseases: the current state of the art. Arch Toxicol Published online Jul 18, 2016;
Endocrine Disorders in Cystic Fibrosis. Pediatr Clin North Am 2016;63(4):699-708.

The Rational Clinical Examination: Evidence-Based Clinical Diagnosis

The Rational Clinical Examination: Evidence-Based Clinical Diagnosis
Make the Diagnosis: Osteoporosis